Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.